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Anti-B7-1 blocks mononuclear cell adherence in vasa recta
after ischemia
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Anti-B7-1 blocks mononuclear cell adherence in vasa recta gen only when a second costimulatory signal, provided
after ischemia. by the “antigen-presenting cell,” is present [2]. Several
Background. Blocking the costimulatory pathway by CTLA-4
T cell molecules may serve as receptors for costimulatoryIg, reactive with both B7-1 and B7-2 costimulatory molecules,
signals, and among them, CD28 is currently the best char-protects the kidney during acute ischemia/reperfusion injury.
This study investigated whether and how B7-1 and/or B7-2 pro- acterized [3]. CD28 has two known ligands, B7-1 (CD80)
teins are involved in renal ischemia/reperfusion injury (IRI). and B7-2 (CD86), both of which are expressed primarily
Methods. Uninephrectomized rats were submitted to warm
on activated antigen-presenting cells. After an interac-renal ischemia (30 min) and received control monoclonal anti-
tion of CD28 with B7, CD28 transduces a signal enhanc-body (mAb; 17E3), anti-B7-1 (3H5), anti-B7-2 (24F), a combi-
nation of anti-B7-1/B7-2, or CTLA-4 Ig. Renal function, mor- ing T-cell proliferation and cytokine secretion. Also pres-
phology, and the kinetics of inflammatory cells were studied ent on T cells, CTLA-4 can bind with both B7-1 and B7-2for a ten-day period. Binding sites of the injected antibodies
with even higher affinity compared with CD28, resultingwere detected by secondary staining with anti-mouse Ab.
Results. Compared with controls, acute renal failure (ARF) in inhibition of T-cell proliferation and cytokine secre-
in the anti-B7-1 group was attenuated both functionally and tion. A recombinant fusion protein consisting of the ex-
morphologically. Anti-B7-1/B7-2 and CTLA-4 Ig also were
tracellular domain of CTLA-4, linked to the constantprotective in IRI. ARF was not altered by anti-B7-2 treatment.
region of IgG1, known as CTLA-4 Ig, therefore actsTwo hours after reperfusion, B7-1 was expressed along the en-
dothelial cells of the ascending vasa recta. Expression of B7-1 as a potent competitive inhibitor of B7:CD28-mediated
increased over time during the first 24 hours and decreased T-cell costimulation in vitro and in vivo [4].
thereafter. Two hours after reperfusion, adherence/accumu-
Blocking the B7 costimulatory pathway with thislation of T cells and monocytes/macrophages was found in
CTLA-4 Ig protects the kidney against cold IRI and resultsthe vasa recta of the ischemic kidney. Anti-B7-1–treated ani-
mals had fewer T cells and monocytes/macrophages in the in decreased expression of inflammatory cytokines [5]. In-
vasa recta compared with controls. Leukocyte accumulation jection of a mutated form of CTLA-4 Ig (CTLA-4Y100 Ig),in these vessels after anti-B7-2 treatment was not different
preferentially binding with B7-1 (CD80), and effectivefrom IRI controls.
Conclusion. These observations strongly support the key in blocking the CD80-dependent responses [6] could not
role of the B7-1 protein in the protection of renal IRI through attenuate acute renal failure (ARF). The authors conse-
inhibition of T cell and monocyte adherence at the level of the quently concluded that B7-2 was responsible for the ad-ascending vasa recta.
verse effects in the process of renal ischemia/reperfusion
injury (IRI).
The question of which mechanism is behind this bene-Studies over the past five years have highlighted the im-
ficial effect of the blockage of the costimulatory pathwayportance of the costimulatory pathway B7-CD28-CTLA-4,
in the process of renal IRI was investigated. We foundwhich is essential to the proliferation of T cells [1]. T cells
will be activated through the T cell receptor by the anti- B7-1 expression along the endothelial cells of the ascend-
ing vasa recta soon after IRI. Anti-B7-1 treatment resulted
in a dramatic decrease of T-cell and monocyte/macro-
Key words: congestion, costimulatory pathway, ischemia-reperfusion,
phage adherence in these vessels. Hence, the costimula-vasa recta, T cell, renoprotection, cell signaling.
tory pathway blockage of B7-1 plays a key role in the
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METHODS abdomen was closed, and rats recovered from anesthesia
under heat-producing lamps prior to their return to meta-Production of monoclonal antibodies
bolic cages. During the entire surgical procedure, ani-
The hybridoma producing the irrelevant control mono- mals were placed on a heating pad, and their temperature
clonal antibody (mAb) 17E3 (anti-human placental alka- was kept constant. Postoperative animals were kept each
line phosphatase) was previously developed in our labora- in a separate cage at constant temperature (18C) and
tory [7]. The hybridoma cell line producing the anti-B7-1 humidity (45%) on a 12-hour light/dark cycle, receiving
(3H5) and the hybridoma producing the anti-B7-2 mono- free tap water and standard rat pellets. Animals were
clonal antibody 24F were obtained from Japan [8]. CTLA-4 weighed daily. A sacrifice of four animals per experimen-
Ig (obtained from M. Waer, K.U.L.), anti-intercellular tal time point of each investigated group was done at 2,
adhesion molecule-1 (anti-ICAM-1; 1A29), and anti-leuko- 6, and 12 hours and then at 1, 2, 5, and 10 days. Blood
cyte function associated molecule-1 (anti-LFA-1; WT-1) samples were taken by heart puncture. Animals surviving
served as positive control mABs in a model of acute more than three days received an additional injection of
the mAb at day 2 (4 mg/kg). All procedures were carriedrenal IRI. Hybridoma cells were grown up as described
out in accordance with the NIH Guide for the Care andby Ghielli et al [9]. Secreted antibodies were purified
Use of Laboratory Animals No. 85-23, 1985.from culture supernatant by affinity chromatography with
protein G (ImmunoSource, Belgium) and dialyzed against
Titers of injected mouse antibodiesphosphate-buffered saline. Denaturing sodium dodecyl
Plasma titers of injected mouse IgG1 were monitoredsulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
by ELISA for IgG1, as described by Ghielli et al [9].in reducing conditions confirmed the absence of contami-
Plasma concentration of mouse antibodies before injec-nation of antibody solutions with non-IgG proteins. The
tion of all groups was beyond 8 106 ng/mL. The plasmaconcentration of 90% pure mAb solutions was deter-
concentrations of injected mAbs were maintained abovemined by enzyme-linked immunosorbent assay (ELISA)
10 g/mL throughout the experiment in all rats.for IgG1 and checked spectrophotometrically at 280 nm.
Pure antibody solutions were assured to contain less Animal sacrifice and renal tissue preparation
than 1 endotoxin unit per mg protein or per mL injection Rats were sacrificed under sodium pentobarbital (60 mg/
solution (LAL, Bio Whittacker, Walkersville, MD, USA). kg) anesthesia by heart puncture. Left kidneys were ex-
The concentration of mAb was brought to 0.75 mg/mL. tracted, decapsulated, rinsed in 0.9% NaCl, and cut into
2 mm thick slices and fixed in methacarn (60% methanol,
Experimental design 10% acetic acid, 30% trichlorethane, 4 hours at room tem-
Before the experiment, male inbred LEW rats (220 to perature) and rinsed in 70% ethanol, dehydrated, and
250 g) were housed in different cages on a 12-hour light– embedded in low-melting point paraffin (52C, BDH
Laboratory Supplies, Poole, UK).dark cycle. After overnight fasting, surgical procedures
were carried out under anesthesia with sodium pentho-
Histological evaluation of renal tubular damagebarbitone (60 mg/kg). After shaving and skin disinfec-
Four-micrometer sections from methacarn-fixed par-tion, rats were covered with a sterile cloth, leaving only
affin-embedded renal tissue were stained with periodictheir abdomen exposed for a subsequent midline incision.
acid and Schiff reagent (PAS) in combination with prolif-All surgical instruments were sterile. The renal pedicle
erating cell nuclear antigen (PCNA) staining (PC10),was clamped for 30 minutes. All animals underwent a
and were counterstained with methyl green (nuclei). Toright nephrectomy at the end of the ischemia and were
evaluate tubular epithelial cell injury in the outer striperandomly assigned to one of the following groups. Just
of outer medulla (OSOM) of each animal, 20 proximalbefore releasing the clamp, rats were subsequently in-
tubular cross-sections were assigned a score indicating
jected intravenously with sterile solutions of one of the
intact tubules (score 0), tubules with lost brush borders
following: mAb 3H5 (mouse IgG1) reactive with B7-1 (score 1), tubules with necrotic or detached cells (50%
(6 mg/kg; N 28); mAb 24F (mouse IgG1) reactive with detachment  score 2 or 50% detachment  score 3),
B7-2 (6 mg/kg; N 28); a combination of mAb 3H5 and and tubules with denuded basement membranes (score 4),
mAb 24F (6 mg/kg of each mAb; N  28); irrelevant small border of cytoplasm with PCNA positive nuclei
control mAb 17E3 against human alkaline phosphatase (score 5), and restoration of the brush border (score 6;
(mouse IgG1; 6 mg/kg; N 28); and CTLA-4 Ig (2 mg/kg, score system [10]).
intravenously [5]; N  28). A positive control group
Immunohistochemical stainingswas injected with a combination of anti-ICAM-1 (clone
1A29) and anti-LFA-1 (clone WT-1; 6 mg/kg of each Polymorphonuclear cells (PMN). Since the myeloper-
oxidase assay, chloroacetate esterase, and HIS48 cross-mAb). After ascertaining reperfusion of the kidney, the
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The staining procedure was performed as prescribed in
the Dako ARK Kit (Dako Corporation, California,
USA) for immunohistochemical staining using mouse
primary mAbs in mice or in rats injected with mouse
mAbs (Prosan; Dako). Prior to the application of the
primary mAbs to the specimen, the antibody was labeled
using secondary biotinylated anti-mouse immunoglobu-
lin. This primary antibody [ED-1 (1/100) or HIS17 (1/30)]
and the secondary biotinylated anti-mouse immunoglob-
ulin were mixed in solution, resulting in the binding of
biotinylated secondary mAb to the primary mAb. Then
normal mouse serum was added to the solution in order
to bind the residual biotinylated anti-mouse immuno-
globulin, thus avoiding a potential interaction with immu-
noglobulin endogenous in the specimen. Biotin-labeled
primary antibody was applied to the specimen for 15
minutes. The specimen was next incubated for 15 min-
utes with streptavidine-peroxidase (Dako ARK Kit).
Slides were washed in Tris-buffered saline. Then the
peroxidase substrate solution (20 L DAB chromogen
solution in 1 mL buffered substrate) was added to the
slides for five minutes. Sections were lightly counter-
stained with methyl green and covered in glycerin-gela-
tin. An irrelevant mouse IgG1 served as the control
staining. In the OSOM and in the medulla (20 micro-
scopic fields), positive cells were counted and expressed
as cells per square millimeter.
Fig. 1. HIS17 as marker for T-cell accumulation/infiltration. (A) Isch-
In vivo immunohistochemical detection of B7-1 and B7-2.emic kidneys were stained with a CD4 marker (mAb W3/25) and with
HIS17 (CD43). The number of W3/25 (CD4)-positive cells () is compa- Four micrometer sections from paraffin-embedded tissue
rable with the number of HIS17-positive cells (). In addition, both were washed in Tris-buffered saline (0.01 mol/L Tris-
monoclonal antibodies were checked on a rat spleen section. (B) HIS17
HCl, pH 7.6, in 0.9% NaCl) that was supplemented withstained the region of T cells, comparable to W3/25 (CD4).
0.1% Triton X-100. To investigate the binding sites of the
injected monoclonal antibodies, sections were incubated
(30 min) with biotinylated horse anti-mouse secondaryreact with mφ/m	 [10], standard hematoxylin-eosin stain-
antibody. Then sections were incubated for 60 minutesing was performed to estimate the PMN presence, based
with avidin-biotin complex (Vectastain; Vector Labora-on the morphology of the nucleus.
tories, Burlingame, CA, USA). The peroxidase substrateMonocytes/macrophages and T cells. Staining for mac-
solution [20 mg 3-amino-ethyl-carbazole (Sigma Chemi-rophages was performed using mAb ED1 [11]. HIS 17
cal Co., St. Louis, MO, USA) in 24 mL dimethyl sulfox-was used for staining T cells reacting with CD43, which
ide, 200 mL acetate, pH 5 to 5.2, and 4 mL 0.3% H2O2]also was present on the neutrophils and, as we demon-
was added. Sections were lightly counterstained withstrated, was not prominent after renal IRI [10, 12]. As
methyl green and covered in glycerin-gelatin. Nonische-the control staining, we used a CD4 antibody (W/35, that
mic rats, injected with anti-B7-1 or anti-B7-2, served asalso cross-reacted with a subpopulation of monocytes
controls. Two hours after circulation of the antibodies,[13]). The number of CD4 cells (stained by mAb W3/
animals were sacrificed as described previously in this25) was compared with the number of HIS17-positive
article. Expression was quantified with an image analysiscells after renal IRI as shown in Figure 1A. In addition,
system (Leitz-Aristoplan microscope with a KS-420 colorwe also stained a spleen section (Fig. 1B) with HIS17
image analysis system; Kontron, Nashville, TN, USA).(CD43) and W3/25 (CD4). Both antibodies stained to
Expression in inner stripe of the outer medulla (ISOM)the same intensity and the same number of T cells in
was measured under 250 magnification. Photographsthe white pulp of the periarteriolar sheets. Because both
were captured by a video camera and transferred digi-antibodies cross-react with other cells types and reveal
tally into a computer. The B7 expression was identifiedthe same staining pattern, HIS17 was preferred since
by adjustment of a multicolored threshold in the analysisthis antibody is suitable for paraffin-embedded slides; it
program that was set one time, and readjustment forpreserves the morphology of the kidney sections, com-
pared with the frozen kidney sections (CD4 antibodies). next slides was not performed. All slides were measured
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Fig. 2. Serum creatinine. Anti-B7-1 treatment clearly protects the kidney after IRI (A), whereas treatment with anti-B7.2 does not protect the
ischemic kidney (B). Anti-B7-1/B7-2 (C ), CTLA-4 Ig (D), and anti-ICAM-1/LFA-1 (E ) also protect the kidney after IRI. Symbols are: () IRI
kidney  control mAb; () IRI kidney  treatment. *P  0.05 IRI compared with IRI with treatment (N  4 per group).
in one time point with the same microscope adjustments. B7-1) or with 10 g 24F (anti-B7-2) using an indirect
Data are expressed as percent of pixels reading out of staining protocol as described by Ysebaert et al [10].
total pixels in the observed field.
Statistical analysis
Immunolabeling of rat peripheral blood leukocytes Data are presented as means
 SEM. They were com-
pared with a one-way analysis of variance (ANOVA),Leukocytes present in peripheral whole blood with
and a Student-Newman-Keuls test was used to prove qual-ethylenediaminetetraacetic acid (EDTA) were labeled
with 2.5 g 22601D (anti-CD28) or with 5 g 3H5 (anti- itative differences by using the software package SPSS
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Fig. 3. Morphological evaluation of renal dam-
age. After untreated IRI, morphological in-
jury of the tubular cells was most pronounced
in the outer stripe of the outer medulla and in
the medullary rays; 12 hours after reperfusion,
tubular cell necrosis became apparent in isch-
emic controls. Ischemic kidneys from animals
that received the anti-B7-1 treatment had sig-
nificantly less tubular necrosis compared with
controls at 12 and 24 hours (A). Cellular ne-
crosis of proximal tubules in the anti-B7-2–
treated group was not different from the con-
trol group (B). Ischemic kidneys from animals
that received the combination treatment of
anti-B7-1/anti-B7-2 also had significantly less
cellular necrosis compared with controls at
12 and 24 hours (C ). Ischemic kidneys from
animals that received CTLA-4 Ig also had sig-
nificantly less cellular necrosis compared to
controls at 12 and 24 hours (D). After adminis-
tration of anti-ICAM-1/anti-LFA-1, ischemic
kidneys showed less necrosis compared with
controls at 24 hours after injury (E ). Symbols
are: () IRI kidney  control mAb; () IRI
kidney  treatment. *P  0.05 IRI compared
with IRI with treatment (N  4 per group).
(SPSS, Inc., Chicago, IL, USA). Significant differences the anti-B7-1–treated group (IRI, 3.8 
 0.1 mg/dL; IRI/
anti-B7.1, 2.03 
 0.33 mg/dL; P  0.05 vs. IRI). Anti-were anticipated when P  0.05.
B7-2 could not provide any protection to the kidney in
IRI (IRI, 3.8 
 0.1 mg/dL; IRI/anti-B7.2, 3.52 
 0.8 mg/
RESULTS dL). The combination of anti-B7-1/B7-2 was protective
Clinical observation and body weight on renal IRI (IRI, 3.8 
 0.1 mg/dL; IRIanti-B7-1/anti-
B7-2: 2.65 
 0.1 mg/dL; P  0.05 vs. IRI). In the anti-Because the antibody was used for the first time in vivo,
ICAM-1/anti-LFA-1–treated group, serum creatinineanimals were inspected carefully. No abnormalities in their
levels were significantly lower compared with controlsbehavior and no differences in weight between groups
(IRI, 3.8 
 0.1 mg/dL; IRIanti-ICAM-1/anti-LFA-1,could be observed. No abnormalities in peripheral blood
2.2 
 0.5 mg/dL; P  0.05 vs. IRI).smear, spleen, liver, heart, lungs, intestine, and muscles
were observed in any treated group. No diarrhea occurred,
Morphologyand no hearing loss was observed in any animal.
Cellular necrosis. The amount of cellular necrosis is
Renal function demonstrated in Figure 3. In controls (IRI), injury of
tubular cells was most pronounced in the OSOM andMeasurements of serum creatinine are shown in Fig-
in the medullary rays. Twelve hours after reperfusion,ure 2. Serum creatinine gradually increased in all groups
to a maximum at 24 hours but was significantly lower in tubular cell necrosis became apparent: 60 
 5% of tu-
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Fig. 4. Normal tubules. In the untreated IRI
group 12 hours after reperfusion, a minority
of the proximal tubules of the S3 segment
remained undamaged; only 6% 
 4 of the tu-
bules had a normal appearance with intact
brush border. Forty-eight hours after the onset
of IRI, regeneration started and normal tu-
bules reappeared. Ischemic kidneys of anti-
B7-1–treated animals had significantly more
intact tubules (A). Except for day 5 after IRI,
the amount of normal proximal tubules in the
anti-B7-2–treated group was not different from
controls (B). Ischemic kidneys from animals
receiving anti-B7-1/anti-B7-2 (C ) or CTLA-4
Ig (D) had significantly more intact tubules.
After anti-ICAM-1/anti-LFA-1, more intact
tubules were found from day 1 (E ). Symbols
are: () IRI kidney  control mAb; () IRI
kidney  treatment. *P  0.05 IRI compared
with IRI with treatment (N  4 per group).
bules had naked basement membranes going along with controls 24 hours after injury (IRI 61 
 4% vs. anti-
cell necrosis. Renal damage after anti-B7-2 treatment ICAM-1/anti-LFA-1 29% 
 2%, P  0.01).
was not different from IRI [12 hours, IRI 60 
 5% vs. In the control group, 40 
 5% of the tubules were
anti-B7-2 66 
 11% (P  NS); 24 hours, IRI 61% 
 4 injured for more than 50% six hours after reperfusion.
vs. anti-B7-2 49 
 6% (P  NS)]. In contrast, anti-B7-1 In contrast, only 7 
 1% of the tubules were damaged
treatment revealed significantly less tubular necrosis severely (score 3) in the anti-B7-1 group. In addition, a
compared to controls at 12 hours (IRI 60 
 5% vs. anti- minority of the proximal tubules in the antiB7-1/anti-
B7-1 18 
 3%, P  0.01) and at 24 hours (IRI 61 
 4% B7-2- and the CTLA-4 Ig-treated groups were injured
vs. anti-B7-1 11 
 4%, P  0.01). Treatment with anti- more than 50%. In the latter groups, most of the injured
B7-1/anti-B7-2 resulted in significantly less cell necrosis
tubules showed only a loss of brush border, without signscompared with controls at 12 hours (IRI 60 
 5% vs.
of severe damage. As mentioned before, the severity ofanti-B7-1/anti-B7-2 24 
 6%, P  0.01) and at 24 hours
renal damage in the anti-B7-2–treated animals was not(IRI 61 
 4% vs. anti-B7-1/anti-B7-2 14 
 6%, P 
different from controls. Kidneys of those anti-B7-2–0.01). CTLA-4 Ig treatment resulted in significantly less
treated animals had the same amount of sublethal in-cellular necrosis compared with controls at 12 hours (IRI
jured proximal tubules (score 3 at 12 hours after reper-60 
 5% vs. CTLA-4 Ig 19 
 6%, P  0.01) and at 24
fusion, IRI 23 
 10% vs. anti-B7-2 19 
 5%, P  NS).hours (IRI 61 
 4% vs. CTLA-4 Ig 21 
 5%, P  0.01).
Normal tubules. The amount of normal tubules isAfter the administration of anti-ICAM-1/anti-LFA-1,
the ischemic kidneys showed less necrosis compared with demonstrated in Figure 4. In IRI, 12 hours after reperfu-
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sion, a minority of proximal tubules of the S3 segment
remained undamaged. Only 6% 
 4 of the tubules had
normal appearance with intact brush border. Anti-B7-2
treatment did not change the amount of normal tubules
after 12 hours (IRI 6 
 4% vs. anti-B7-2 4 
 4%, P 
NS) and after 24 hours of reperfusion (IRI 1.6 
 2% vs.
anti-B7-2 1.6 
 2%, P  NS). In the anti-B7-2–treated
group, no differences in kidney regeneration could be
observed when compared to controls as evaluated by
scores 5 and 6 (data not shown). At day 10, almost all
tubules were returned to normal in both groups (IRI
90 
 4% vs. anti-B7-2 87.5 
 6%, P  NS).
In contrast, ischemic kidneys of the anti-B7-1–treated
animals had significantly more intact tubules (12 hours,
IRI 6 
 4% vs. anti B7-1 56 
 2%, P  0.01; 24 hours,
IRI 1.6 
 4% vs. anti B7-1 55 
 5%, P  0.01). Kidneys
of the anti-B7-1–treated animals showed minimal signs
of tubular damage. Consequently, signs of early regener-
ation (score 5), defined as flattened undifferentiated cells,
were almost absent over the entire study period, because
no repair in extenso had to be done.
The first 24 hours after reperfusion, a combination of
anti-B7-1/anti-B7-2 as well as the CTLA-4 Ig group had
more intact tubules after IRI in comparison with controls
(1.6 
 4% vs. anti-B7-1/anti-B7-2 31.5 
 3%, P  0.01;
IRI 1.6 
 4% vs. CTLA-4 Ig 43 
 9%, P  0.01).
Leukocytes in the ischemic kidney
Results of leukocyte accumulation in OSOM and ISOM
are presented in Table 1.
Polymorphonuclear cells: OSM and ISOM. After IRI,
the number of PMN remained unchanged over time.
PMN accumulation was not altered by anti-B7-1, and
anti-B7-2 as well as the combination of anti-B7-1/B7-2,
CTLA-4 Ig, or anti-adhesion compared with IRI animals.
Monocytes/macrophages: OSOM. After IRI, the num-
ber of mφ/m	 increased during the first 24 hours. The
presence of monocytes after anti-B7-2 treatment was not
different from IRI group over the whole study period.
In contrast, monocytes after anti-B7-1 treatment were
significantly lower compared with IRI kidneys.
Monocytes/macrophages: ISOM. An increased num-
ber of mφ/m	 was found after IRI (Fig. 5A). Monocytes
after the anti-B7-2 treatment were not different from
ischemic control kidneys over the entire study period.
In contrast, anti-B7-1 treatment resulted in significantly
fewer monocytes in the ISOM at different time points
after reperfusion (Fig. 5B). This phenomenon also was
found in the CTLA-4 Ig group as well as in the anti-
B7-1/B7-2 and the anti-adhesion group.
T cells: OSOM. During the first 24 hours after IRI,
the number of T cells remained unchanged over time.
The number of T cells after IRI  anti-B7-1 and anti-
B7-2 was not different from control animals. The number
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Fig. 5. Leukocyte accumulation in the vasa recta of the inner stripe of the outer medulla (ISOM) two hours after reperfusion. Two hours after
reperfusion, there was a significant accumulation of T cells in the vessels of the vasa recta in untreated ischemic kidneys (A). In contrast, fewer
T cells were found in those vessels after anti-B7-1 treatment (B). In ischemic kidneys, accumulation of monocytes in the vasa recta could be
observed (C). In contrast, animals injected with anti-B7-1 had significantly fewer monocytes in the medulla of the ischemic kidney (D). Magnification
200 (N  4 per group).
B7-2- and CTLA-4 Ig-treated animals also was not differ- vessels. In contrast, two hours after reperfusion, fewer
T cells were found in the vasa recta in the ISOM afterent from control animals.
T cells: ISOM. Two hours after IRI, there was a sig- anti-B7-1 treatment (Fig. 5D). This phenomenon also
was observed in the animals treated with anti-B7-1/anti-nificant accumulation of T cells in the vessels of the vasa
recta in untreated animals (Fig. 5C). Indeed, during the B7-2 and those treated with CTLA-4 Ig.
first 24 hours post-IRI, a bead-like appearance of T cells
In vivo immunohistochemical detection of B7-1in the ISOM could be observed, strongly suggesting that
these cells remain intravascular. The administration of In vivo immunohistochemical staining of ischemic kid-
neys originated from rats injected with mAb anti-B7-1anti-B7-2 could not prevent T-cell accumulation in those

Fig. 6. In vivo immunohistochemical staining of B7-1. Animals injected with an irrelevant control antibody of the same isotype (17E3) showed
no positivity in the ischemic kidney (A; N 4 per group). Normal kidneys in the absence of IRI that were injected with anti-B7-1 also showed
no positivity in the kidney (B; N  4 per group). The in vivo immunohistochemical staining of ischemic kidneys originated from the rats injected
with the monoclonal antibodies with anti-B7-1 showed intense positivity at the vasa recta of the kidney (C–H). (D) A histotopographic cross-
section through the ISOM [13]. The vascular bundles are fully developed in this zone of the kidney. The thin and thick limbs of the juxtamedullary
nephrons are situated near the bundles ( arterial vessel, venous vessel, thin limbs, collecting ducts, thick ascending limbs) [13]. Injected
mAb anti-B7-1 was found at these vascular bundles located in the ISOM (C and G). The expression of B7-1 in the ISOM (in area %) was measured
histomorphometrically as shown in (H). The expression increased early after reperfusion and increased in time with a maximal expression after
24 hours after reperfusion. It was clear that the expression of B7-1 was found on the endothelial cells of the vasa recta with a flattened irregular
shape (E), indicating that the expression was found on the ascending venous vessels (F). Magnification A and E, 250; B, C, and G, 100.
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Fig. 7. Flow cytometry of peripheral blood
with CD28. Normal scatter profile of rat pe-
ripheral cells (A), with a mononuclear cell re-
gion (R1) and polymorphonuclear cell region
(R2). Labeling of rat peripheral cells with anti-
CD28 stained a population of leukocytes (B),
indicated by R3. Back-gating of the positive
labeled cells with CD28 in region R3 clearly
showed that almost all of them were located
in the mononuclear cell cluster, region R1 (C )
and not in the polymorphonuclear cell region
R2. In addition, the functionality of the anti-
bodies anti-B7-1 (D) and anti-B7-2 (E ) can
be seen. By flow cytometry, after injection of
the antibodies in rats, anti-B7-1 and anti-B7-2
both bind on rat circulating monocytes.
showed intense positivity at the vasa recta of the kidney, Expression of B7-2 was less than B7-1 over the entire
time period.reflecting B7-1 expression on these endothelial cells
(Fig. 6C, E, G). Animals injected with an irrelevant con- B7-1 expression was found on vessels with a flattened
irregular shape (Fig. 6E), suggesting that the protein istrol antibody of the same isotype (17E3) showed no positi-
vity on the endothelial cells of the vasa recta, as shown expressed mainly on the endothelial cells of the ascend-
ing venous vessels (Fig. 6F) [14]. Expression of ICAM-1in Figure 6A. Normal kidneys without IRI that were
injected with anti-B7-1 showed no positivity at the vasa was found on endothelial cells of the vasa recta.
recta (Fig. 6B).
Flow cytometry of peripheral blood with CD28Two hours after IRI, anti-B7-1 stained promptly the
vasa recta of the inner stripe of the outer medulla (Fig. Some of the leukocytes (38.6%) were positive for CD28.
Back-gating of the positively labeled cells with CD286C). The expression of B7-1 extended over time (Fig. 6H).
There was no positivity in the cortex or in the glomeruli, clearly showed that most of those were located in the
mononuclear cell cluster (Fig. 7C). Only 4.1% of thenor was there staining on the peritubular capillaries.
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positive cells were located in region 2, that is, the region ated with prevention of mφ/m	 and T cell adhesion/accu-
mulation in those vessels.of the polynucleated cells with a high FSC/high SSC light
From the growing series of studies examining the rolescatter profile.
of leukocyte adhesion molecules in renal ischemic injuryPeripheral leukocytes were labeled with mouse anti-
using monoclonal antibodies, it has become clear thatrat anti-B7-1 (3H5; Fig. 7D) and 29.13% of all leukocytes
the leukocyte adhesion molecules CD11a/CD18 [21, 22]were positive for B7-1.
and CD11b/CD18 [22], and especially ICAM-1 [21, 23–Peripheral leukocytes were labeled with mouse anti-
26], mediate renal IRI in both rat and mouse models. Therat anti-B7-2 (Fig. 7E) and 31.28% of all leukocytes were
administration of antisense oligonucleotides to ICAM-1positive for B7-2.
mRNA in rats had similar effects [27]. Interestingly, a
delayed administration of anti-ICAM-1 for eight hours
DISCUSSION after reperfusion did not protect the kidney [21]. Given
Although in recent years substantial progress has been the fact that the effect of an anti-adhesion approach is
early after the onset of injury, it is likely that its effectmade concerning the costimulatory pathway controlling
should be sought at the level of the endothelial cells.the activation of the lymphocyte population, its role in
Support for this theory also comes from studies showingIRI is a provocative but poorly understood phenomenon.
interactions between endothelial cells and inflammatoryThe B7-CD28-CTLA-4 pathway is essential in the prolif-
cells, as well as interactions between different types oferation of T cells after T-cell-antigen recognition [1].
leukocytes in the vasa recta after ARF [28]. One hourCTLA-4 Ig was originally developed as an agent that
after reperfusion, Kelly et al showed an increased expres-would inhibit or prevent T cell activation. Since CTLA-4
sion of ICAM-1 on endothelial cells of the vasa recta,Ig was used in the treatment of psoriasis vulgaris [15],
leading to the aggregation of leukocytes [21]. The earlythis drug “finally graduated to the clinic” [16]. Also, in
and intravascular effect of the anti-adhesion approacha model for Goodpasture’s disease, CTLA-4 Ig amelio-
is supported by its use in a toxic model of ARF (mercuryrated autoimmune glomerulonephritis [17].
chloride): No protection could be observed after admin-Chandraker et al demonstrated that the B7–T-cell co-
istration of anti-ICAM-1/anti-LFA-1 in this particularstimulatory activation pathway plays a key role in IRI
model [9], in which no alterations of the microcirculationsince injection of CTLA-4 Ig prevented transient renal
after ARF could be observed [29].dysfunction and cell infiltration [5, 18]. Chandraker et al
Ysebaert et al dissected the different cell types adher-injected a mutated form of CTLA-4 Ig that preferentially
ing and/or infiltrating into the kidney after IRI and foundbound with B7-1 (CD80) and was effective in blocking
mainly mononuclear cells. He and others found no in-CD80-dependent responses [6]. This mutated CTLA-4
crease in the number of PMN after renal IRI, when usingY100F could not attenuate ARF. Hence, they concluded
appropriate staining methods [10]. T cells did not infil-that it was not B7-1, but B7-2 that was responsible for
trate or proliferate in the OSOM of the kidney before
the adverse effects in the process of IRI [5]. On the other
day 3, and by that time the kidney function had already
hand, these authors demonstrated that B7-1 mRNA, us- recovered [10]. In our study, there was no significant
ing a specific primer for CD80, was significantly up-regu- increase in the number of T cells in the OSOM in the
lated already one day after IRI and that CTLA-4 Ig first 24 hours after the onset of injury. In contrast, in the
could prevent the up-regulation of B7-1 mRNA [18]. ISOM, T cells as well as mφ/m	 significantly adhered/
We confirmed the involvement of the costimulatory accumulated in the vasa recta already at two hours after
pathway in IRI by CTLA-4 Ig as described by Chandraker reperfusion. These results support a critical role for T cells
et al [5, 18]. In contrast to those authors, we found B7-1 in the pathogenesis of ischemia/reperfusion injury, as
to be involved in IRI and could not confirm the role of nicely demonstrated by the Rabb et al, who found that
the B7-2 molecule in this process. Support for B7-1 rather mice deficient in both CD4 and CD8 T-cells had less
than B7-2 involvement came from in vitro studies by renal injury after ischemia/reperfusion injury [30]. Renal
Hathcock et al showing that blocking the B7-2 molecule function was markedly improved in nude nu/nu mice
requires 100 times more CTLA-4 Ig than is required for compared with postischemic controls. Adoptive transfer
blocking B7-1 costimulation [19]. Khoury pointed out of T cells into these nu/nu mice demonstrated a reconsti-
that the dose used in vivo preferentially inhibits the B7-1 tution of injury phenotype [30].
pathway and spares the B7-2 pathway [20]. We found B7-1 expression on the endothelial cells of
In addition, we identified the critical localization of the ascending vasa recta two hours after reperfusion.
the B7-1 protein at the level of the endothelial cells of Interestingly, B7-1 expression was mainly localized on
the ascending vasa recta. Hence, the central role of the the ascending vasa recta, suggested by the flattened, ir-
costimulatory pathway has started to unravel, since our regularly shaped cross-section of B7-1–positive vessels
[14]. It is known that in most organs, venules have thecurrent study shows that treatment of anti-B7-1 is associ-
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